SynthesisBMC cancer2021
Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review.
Synthesis in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 23 citations in OpenAlex.
- Immunological Determinants of Oncogenic Virus-Driven Cancers in Africa: Mechanisms, Co-Infections and Public Health Challenges.Pathogens (Basel, Switzerland) · 2026Review
- Liver disease diagnostics and access barriers in African settings: a narrative review.Journal of clinical pathology · 2026Review
- Challenges in the Diagnosis of Hepatocellular Carcinoma in a 32-Year-Old Male With Hepatitis B and Alcohol Use.Clinical case reports · 2026Article
- Burden and Clinical Impact of Hepatitis D Virus Co-Infection Among HBsAg-Positive Patients in Mauritania.Diseases (Basel, Switzerland) · 2026Article
- Establishing cancer registries in Africa - focus on hepatopancreatobiliary cancers.Nature reviews. Gastroenterology & hepatology · 2026Review
- A report from the Second Tanzania Liver Cancer Conference (TLCC) 2025 - leading the fight against liver cancer in Sub-Saharan Africa.Ecancermedicalscience · 2026Article
- Hepatocellular Carcinoma in Africa: Epidemiology, Prevention and Outcomes.Current hepatology reports · 2026Review
- Deciphering the oncogenic role of Rac family small GTPase 3 in hepatocellular carcinoma through multiomics integration.World journal of hepatology · 2025Article
- Pragmatic Approach to Hepatocellular Carcinoma Diagnosis in High-Incidence, Resource-Limited Settings in Africa.JCO global oncology · 2025Article
- Leading the fight against liver cancer in Sub-Saharan Africa: developing the first multidisciplinary liver tumour board in Tanzania.Ecancermedicalscience · 2025Article
- Hepatitis B and hepatitis C virus infections and associated factors among prisoners in Gondar City, Northwest Ethiopia.PloS one · 2024Article
- [Delta hepatitis in Africa: epidemiological and clinical particularities].Medecine tropicale et sante internationale · 2023Review
- Therapeutic options in hepatocellular carcinoma: a comprehensive review.Clinical and experimental medicine · 2023Review
- Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial).JHEP reports : innovation in hepatology · 2023Article
- Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV.PloS one · 2023Observational
- Malignancy and viral infections in Sub-Saharan Africa: A review.Frontiers in virology (Lausanne, Switzerland) · 2023Article
- Hepatocellular Carcinoma in Africa: Challenges and Opportunities.Frontiers in medicine · 2022Article
- Article
- Drastic sex-dependent etiological distribution in severe liver diseases from Gabon.Frontiers in oncology · 2022Article
- How Viruses Use the VCP/p97 ATPase Molecular Machine.Viruses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in Africa. In Africa, the major causes of HCC include chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). Knowledge of the changes in the incidence of viral hepatitis-associated HCC over time and the factors responsible for such changes is key in informing policies for the prevention of viral hepatitis-associated HCC in Africa.
aimThe study aimed to systematically summarize the changes in the prevalence of viral hepatitis among HCC patients and the overall effect of the prevalence of viral hepatitis on the incidence of HCC over the past four decades in Africa (1980-2019).
methodsA literature search was conducted in MEDLINE (PubMed), Google Scholar, Science Direct, Scopus, Web of Science, and African wide web for articles published on viral hepatitis-associated HCC in Africa from 1980 to 2019. The abstracts of the articles were screened for eligibility and those meeting the inclusion criteria were retrieved and reviewed.
resultsA total of 272 studies were included in the analysis. Viral hepatitis-related HCC incidence changed by 1.17% (95% confidence interval (CI): 0.63-1.71, p < 0.001), 0.82% (95% CI: 0.45-1.18, p < 0.001), and 3.34% (95% CI: 2.44-4.25, p < 0.001) for every 1% change in the prevalence of HBV, HCV, and hepatitis D virus (HDV) respectively, per decade. The incidence of HBV-related HCC decreased by - 0.50% (95% CI: - 0.74 - - 0.25, p < 0.001) over the last 40 years, while HCV-related HCC increased.
conclusionOverall, the incidence of viral hepatitis-associated HCC has not declined, mainly due to no decline in the prevalence of HCV, HDV, and the high number of chronic hepatitis B carriers on the African continent. There is an urgent need for the allocation of resources for the implementation of treatment and preventive programs for HBV, HCV, HDV, and HCC in Africa. This systematic review is registered with PROSPERO®, number CRD42020169723.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.